Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer

scientific article

Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1200/JCO.1998.16.11.3528
P698PubMed publication ID9817271

P2093author name stringM Green
S Bernard
J E Herndon
L Leone
R W Carey
S Seagren
J Rosenman
C T Chung
N C Choi
P433issue11
P407language of work or nameEnglishQ1860
P921main subjectchemotherapyQ974135
lung cancerQ47912
P304page(s)3528-3536
P577publication date1998-11-01
P1433published inJournal of Clinical OncologyQ400292
P1476titlePhase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer
P478volume16

Reverse relations

cites work (P2860)
Q34671664A Phase I Study of Concurrent Chemotherapy (Paclitaxel and Carboplatin) and Thoracic Radiotherapy with Swallowed Manganese Superoxide Dismutase Plasmid Liposome Protection in Patients with Locally Advanced Stage III Non-Small-Cell Lung Cancer
Q37293955A pooled analysis of limited-stage small-cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy: CALGB 30904.
Q47557590Barriers to Combined-Modality Therapy for Limited-Stage Small-Cell Lung Cancer
Q34501938Chemoradiation schedules--what radiotherapy?
Q38155779Comparison of once and twice daily radiotherapy for limited stage small-cell lung cancer.
Q36051734Comparison of once daily radiotherapy to 60 Gy and twice daily radiotherapy to 45 Gy for limited stage small-cell lung cancer
Q35543239Complex and controversial issues in locally advanced non‐small cell lung carcinoma
Q41380574Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial
Q54953051Current standards for clinical management of small cell lung cancer.
Q34384459Development of treatment strategies in locally advanced non-small cell lung cancer (take home messages).
Q33413185Effect of early chemoradiotherapy in patients with limited stage small cell lung cancer
Q34727914Feasibility and efficacy of simultaneous integrated boost intensity-modulated radiation therapy in patients with limited-disease small cell lung cancer
Q37694009Hypo- or conventionally fractionated radiotherapy combined with chemotherapy in patients with limited stage small cell lung cancer
Q55093161Impact of radiation dose on concurrent chemoradiotherapy for limited-stage small-cell lung cancer.
Q35583915Limited-stage small cell lung cancer: current chemoradiotherapy treatment paradigms
Q35543182Limited‐disease small‐cell lung cancer
Q35120111Lung cancer 5: state of the art radiotherapy for lung cancer
Q34913450Methodological issues in radiation dose-volume outcome analyses: summary of a joint AAPM/NIH workshop
Q79782954Mid-course thoracic radiotherapy with cisplatin-etoposide chemotherapy in limited-stage small-cell lung cancer
Q35198443New approaches for small-cell lung cancer: local treatments
Q94063981Once Daily High-dose Radiation (≥60 Gy) Treatment in Limited Stage Small Cell Lung Cancer
Q84495886Once-daily radiotherapy to > or =59.4 Gy versus twice-daily radiotherapy to > or =45.0 Gy with concurrent chemotherapy for limited-stage small-cell lung cancer: a comparative analysis of toxicities and outcomes
Q38732983Optimal Radiation Therapy for Small Cell Lung Cancer
Q45255415Phase I study of cisplatin and irinotecan combined with concurrent hyperfractionated accelerated thoracic radiotherapy for locally advanced non-small cell lung carcinoma
Q36041017Phase II study of accelerated high-dose radiotherapy with concurrent chemotherapy for patients with limited small-cell lung cancer: Radiation Therapy Oncology Group protocol 0239.
Q37242284Phase II study of tirapazamine, cisplatin, and etoposide and concurrent thoracic radiotherapy for limited-stage small-cell lung cancer: SWOG 0222.
Q74017032Plasmid/liposome transfer of the human manganese superoxide dismutase transgene prevents ionizing irradiation-induced apoptosis in human esophagus organ explant culture
Q36302195Positron emission tomography/computed tomography-guided intensity-modulated radiotherapy for limited-stage small-cell lung cancer
Q33902741Predictors of pulmonary toxicity in limited stage small cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy: CALGB 30904.
Q37626969Progress in the management of limited-stage small cell lung cancer
Q35687700Progress in the therapy of small cell lung cancer
Q36526895Protocol for the CONVERT trial-Concurrent ONce-daily VErsus twice-daily RadioTherapy: an international 2-arm randomised controlled trial of concurrent chemoradiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with lim
Q35576272Radiation Dose Intensification in Limited-Stage Small-Cell Lung Cancer
Q35552410Radiation dose escalation in limited-stage small-cell lung cancer
Q43886078Radiation therapy for small-cell lung cancer: results of the 1995-1997 patterns of care process survey in Japan
Q33339670Randomized comparison of early versus late hyperfractionated thoracic irradiation concurrently with chemotherapy in limited disease small-cell lung cancer: a randomized phase II study of the Hellenic Cooperative Oncology Group (HeCOG).
Q35124160Routine use of approximately 60 Gy once-daily thoracic irradiation for patients with limited-stage small-cell lung cancer
Q36334696Simultaneous integrated dose reduction intensity-modulated radiotherapy applied to an elective nodal area of limited-stage small-cell lung cancer
Q44676670Small cell carcinoma of the head and neck: report of three cases
Q37937880Small cell lung cancer: new clinical recommendations and current status of biomarker assessment
Q37772816Small cell lung cancer: past, present, and future
Q78027906Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 100 patients with small-cell lung cancer: a mature follow-up report
Q34501946The treatment of limited small cell lung cancer: a report of the progress made and future prospects
Q34384504Thoracic radiotherapy in the treatment of limited disease of small-cell cancer: sequence and fractionation
Q37301691Tomorrow's cancer treatments today: the first 50 years of the Cancer and Leukemia Group B.
Q41357983Treatment of limited disease small cell lung cancer: the multidisciplinary team
Q53705076Which fractionation of radiotherapy is best for limited-stage small-cell lung cancer?
Q77956067[Accelerated hyperfractionated compared with conventional radiotherapy in limited small-cell lung carcinoma, with concurrent chemotherapy]
Q73343084[What are the optimal thoracic radiotherapy modalities in limited small cell lung cancer? Review of recent clinical trials.]

Search more.